Inactive Instrument

Highlights OvaScience Inc Nasdaq

Equities

US69014Q1013

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Millendo Therapeutics : Tempest Closes Merger with Millendo and Completes PIPE Financing (Form 8-K)	21-06-28	PU
Reverse Split: 1 of 15	21-06-27	FA
Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	21-06-24	CI
Millendo Therapeutics : Tempest and Millendo Announce Stockholder Approval of Merger (Form 8-K)	21-06-23	PU
Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	21-06-22	MT
MILLENDO THERAPEUTICS, INC. : Other Events (form 8-K)	21-06-11	AQ
Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND	21-04-07	BU
Tempest Therapeutics, Inc and Millendo Therapeutics, Inc Merger Call.	21-03-29	FA
Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	21-03-29	MT
Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Millendo Therapeutics : Tempest and Millendo Announce Proposed Merger Agreement	21-03-29	BU
Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	21-03-28	CI
Millendo Therapeutics, Inc. Announces Discontinue Further Investment in MLE-301	21-01-05	CI
Millendo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Millendo Therapeutics Announces Initiation of First-In-Human Clinical Trial of MLE-301, A Selective NK3R Antagonist	20-09-24	CI
Millendo Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-08	CI
Millendo Therapeutics, Inc. Announces Topline Results for Pivotal Phase 2B Study of Livoletide in Patients with Prader-Willi Syndrome	20-04-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OvaScience Inc Nasdaq

Equities

US69014Q1013

Highlights

Filters